NCT07808073 · Eli Lilly and Company
A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy
What this study is about
The main purpose of this study is to assess how well LY4329090 is tolerated and what side effects may occur in healthy participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Study participants will be in one of 2 parts.
View original scientific description
The main purpose of this study is to assess how well LY4329090 is tolerated and what side effects may occur in healthy participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Study participants will be in one of 2 parts. For each participant in Part A, the study will last about 10 weeks and will include a stay in the Clinical Research Unit (CRU) lasting 5 nights along with 5 outpatient visits to the CRU. For each participant in Part B, the study will last about 21 weeks and will include 4 stays totaling 11 nights along with 14 outpatient visits to the CRU.
Interventions
DRUG
LY4329090
Administered SC
DRUG
Placebo
Administered SC
Primary outcome measures
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time frame: End of Study (Week 28)
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Participant must be 18 (21 for Singapore site) to 65 years of age, inclusive, at the time of signing the informed consent.
- Are overtly healthy with no comorbidities related to body mass index (BMI).
- Have a BMI between 27.0 kilograms per square meter (kg/m²) and 40.0 kg/m², inclusive.
- Have had a self-reported stable weight for 3 months prior to screening.
Exclusion criteria
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders.
- Have a history of chronic medical conditions involving the heart, liver, or kidneys.
- Have either
- ongoing asymptomatic bradycardia defined as less than 50 beats per minute at screening visit
- electrocardiogram (ECG) findings at screening visit of second-degree atrioventricular block or higher, or
- history of symptomatic bradycardia with uncorrected etiology, including diagnosis of sick sinus syndrome.
- Have an abnormal blood pressure and/or pulse rate at screening.
- Have an obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity.
- Have any of the following:
- a diagnosis of hypocalcemia or hypercalcemia, or
- confirmed abnormal laboratory values for calcium and serum phosphorus.
- Have a known, clinically significant gastric emptying abnormality, have undergone weight loss surgery, or have had endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months.
- Have been diagnosed with type 1 or type 2 diabetes mellitus or have glycated hemoglobin A1c (HbA1c) greater than or equal to (≥) 6.5 percent (%) or 48 millimoles per mole (mmol/mol) at screening.
- Have a history or presence of psychiatric disorders, within the last 2 years, that would present a safety risk or may significantly impair the participant's ability to comply with study procedures.
- Have taken any glucose-lowering medications, including insulin, in the past 3 months before screening.
- Have received any drugs from the incretins class within 90 days prior to screening.
- Have been treated within 3 months prior to screening or plan to be treated with prescription medications that promote weight loss.
- Intend to use any weight loss medications during study participation.
- Prior (within 6 months) or planned (during the study) device-based treatment use for obesity.
Where
- Daytona Beach, Florida
- Dallas, Texas
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Oct 8, 2026 · Source of record for eligibility and locations